In lung cancer patients who received the NF-κB inhibitor, the serum levels of IL-1β were increased, and co-treatment of an IL-1R antagonist and the NF-κB inhibitor decreased formation of lung cancer in mice60. The gene discussed is IL1R1; the disease is lung carcinoma.